Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: A naturalistic study

Pharmacopsychiatry

Volumn 46, Issue 2, 2013, Pages 69-76

  Kohler S ^a   Unger, T ^b   Hoffmann, S ^b   Steinacher, B ^c   Fydrich, T ^d   Bschor, T ^e,f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Kliniken im Theodor Wenzel Werk   (Germany)

^c Vivantes Wenckebach Klinikum   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e Schlosspark Klinik   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

antidepressants; depression; depression treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; LITHIUM; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DRUG CHOICE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATURALISTIC INQUIRY; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84875223010     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1323677     Document Type: Article

References (38)

1. Rush A. J., Trivedi M. H., Wisniewski S. R. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry: 2006; 163 1905 1917 (Pubitemid 44807782)
2. Judd L. L., Paulus M. J., Schettler P. J. et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry: 2000; 157 1501 1504
3. Bschor T. Therapy-resistant depression. Expert Rev Neurother: 2010; 10 77 86
4. Connolly K. R., Thase M. E. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs: 2011; 71 43 64
5. Bschor T., Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand: 2010; 121 174 179
6. Papakostas G. I., Fava M., Thase M. E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry: 2008; 63 699 704 (Pubitemid 351329277)
7. Thase M. E. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry: 2011; 56 317 323
8. Souery D., Serretti A., Calati R. et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry: 2011; 12 364 375
9. Crossley N. A., Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry: 2007; 68 935 940 (Pubitemid 47015495)
10. Nelson J. C., Papakostas G. I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry: 2009; 166 980 991
11. Nierenberg A. A. Switch or augment? Lessons from STAR D. Ann Clin Psychiatry: 2011; 22 03 S4 S8
12. Markowitz J. C. Evidence-based psychotherapies for depression. J Occup Environ Med: 2008; 50 437 440 (Pubitemid 351522782)
13. Willich S. Randomisierte kontrollierte Studien - pragmatische Ansätze erforderlich. Dtsch Ärzteblatt: 2006; 103 A2524 A2529
14. Kaptchuk T. J. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol: 2001; 54 541 549 (Pubitemid 32453346)
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry: 1960; 23 56 62
16. Hiller W., Zaudig M., Mombour W. IDCL: ICD-10 Checklists. Göttingen Hogrefe: 2005
17. DGPPN B, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW for the guideline group unipolar depression* S3-Guideline/National Guideline for unipolar depression (in German). Berlin, Düsseldorf DGPPN, ÄZQ, AWMF: 2009; [cited 2009]; 1. [available from: www.dgppn.de, www.versorgungsleitlinien.de, www.awmf-leitlinien.de ]
18. Beck A. T., Ward C. H., Mendelson M. et al. An inventory for measuring depression. Arch Gen Psychiatry: 1961; 4 561 571
19. Derogatis L. R., Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med: 1983; 13 595 605 (Pubitemid 13019024)
20. Endicott J., Spitzer R. L., Fleiss J. L. et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry: 1976; 33 766 771
21. Guy W. Clinical Global Impression. In: Guy W. (ed.). ECDEU Assessment Manual for Psychopharmacology.: 1976
22. First M., Gibbon M., Spitzer R. Structured Clinical Interview for DSM-IV Axis II Disorders. New York NY Biometrics Research Dept, NewYork State Psychiatric Institute: 1996
23. Olejnik S., Algina J. Measures of effect size for comparative studies: applications, interpretations, and limitations. Contemp Edu Psychol: 2000; 25 241 286
24. CIPS International scales for psychiatry. (CIPS) CIPS (ed.). Göttingen Beltz Test GmbH: 2005
25. Seemüller F., Riedel M., Obermeier M. et al. Outcomes of 1 014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol: 2010; May; 20 05 346 355 Epub 2010 Jan 22
26. Bauer M., Pretorius H. W., Constant E. L. et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry: 2009; 70 540 549
27. Berman R. M., Marcus R. N., Swanink R. et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry: 2007; 68 843 853 (Pubitemid 47015482)
28. Trivedi M. H., Thase M. E., Osuntokun O. et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry: 2009; 70 387 396
29. Carpenter L. L., Yasmin S., Price L. H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry: 2002; 51 183 188 (Pubitemid 34127908)
30. Blier P., Ward H. E., Tremblay P. et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry: 2010; 167 281 288
31. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci: 2009; 110 14 28
32. Davies M. A., Sheffler D. J., Roth B. L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev: 2004; 10 317 336 (Pubitemid 40128915)
33. Pira L., Mongeau R., Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol: 2004; 504 61 64 (Pubitemid 39410724)
34. Carroll B. J. Antipsychotic drugs for depression? Am J Psychiatry: 2010; 167 216 author reply 219
35. McCullough J. P. Jr. Treatment for chronic depression using cognitive behavioral analysis system of psychotherapy (CBASP). J Clin Psychol: 2003; 59 833 846
36. UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet: 2003; 361 799 808
37. Mulder R. T., Frampton C., Joyce P. R. et al. Randomized controlled trials in psychiatry. Part II: their relationship to clinical practice. Aust N Z J Psychiatry: 2003; 37 265 269 (Pubitemid 36833755)
38. Porter R., Frampton C., Joyce P. R. et al. Randomized controlled trials in psychiatry. Part 1: methodology and critical evaluation. Aust N Z J Psychiatry: 2003; 37 257 264 (Pubitemid 36833754)